Key Points
- CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics on Feb. 2 at an average price of $46.02, for proceeds of $690,300, according to an SEC Form 4 filing.
- Bernstein has been selling repeatedly in recent weeks, including 45,000 shares on Dec. 29, 4,432 on Jan. 2, 412 on Jan. 5, and 25,156 on Jan. 7, suggesting sustained insider selling activity.
- MAZE shares are trading near $48 with a market cap of about $2.32 billion; analysts have a consensus "Buy" rating and a $44.50 average price target, while the 50-day and 200-day SMAs are $41.48 and $29.71, respectively.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $46.04, for a total value of $230,200.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at $596,908.60. This trade represents a 27.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amy Bachrodt also recently made the following trade(s):
- On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $45.52, for a total value of $227,600.00.
- On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $39.15, for a total value of $195,750.00.
- On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total value of $405,800.00.
- On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.08, for a total transaction of $200,400.00.
Maze Therapeutics Stock Up 0.4%
NASDAQ MAZE opened at $48.14 on Thursday. The stock has a market capitalization of $2.32 billion and a P/E ratio of -2.30. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $48.94. The firm has a 50-day moving average price of $41.48 and a 200 day moving average price of $29.71.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. HC Wainwright restated a "buy" rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. Raymond James Financial began coverage on Maze Therapeutics in a research note on Thursday, November 13th. They set an "outperform" rating and a $48.00 price target on the stock. Wedbush boosted their target price on Maze Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a research report on Friday, November 7th. BTIG Research lifted their price target on Maze Therapeutics from $37.00 to $46.00 and gave the stock a "buy" rating in a research note on Friday, January 16th. Finally, Guggenheim reissued a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $44.50.
Read Our Latest Research Report on Maze Therapeutics
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its position in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Maze Therapeutics during the 4th quarter valued at $39,000. Legal & General Group Plc increased its holdings in shares of Maze Therapeutics by 23.0% during the 3rd quarter. Legal & General Group Plc now owns 5,219 shares of the company's stock worth $135,000 after buying an additional 977 shares during the last quarter. Bank of America Corp DE raised its position in shares of Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock worth $71,000 after buying an additional 1,455 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock worth $49,000 after purchasing an additional 1,725 shares during the period.
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
